A detailed history of Raymond James & Associates transactions in Spdr Ser Tr Spdr S&P Pharmaceu stock. As of the latest transaction made, Raymond James & Associates holds 7,602 shares of XPH stock, worth $345,967. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,602
Previous 7,229 5.16%
Holding current value
$345,967
Previous $287,000 17.42%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$39.24 - $45.31 $14,636 - $16,900
373 Added 5.16%
7,602 $337,000
Q2 2024

Jul 19, 2024

BUY
$39.09 - $42.64 $35,650 - $38,887
912 Added 14.44%
7,229 $287,000
Q1 2024

Apr 22, 2024

BUY
$41.38 - $45.49 $5,544 - $6,095
134 Added 2.17%
6,317 $272,000
Q4 2023

Jan 16, 2024

SELL
$35.2 - $41.92 $225,033 - $267,994
-6,393 Reduced 50.83%
6,183 $257,000
Q3 2023

Oct 24, 2023

BUY
$39.75 - $44.12 $113,804 - $126,315
2,863 Added 29.48%
12,576 $499,000
Q2 2023

Jul 25, 2023

BUY
$39.1 - $42.57 $93,605 - $101,912
2,394 Added 32.71%
9,713 $398,000
Q1 2023

Apr 14, 2023

BUY
$39.61 - $44.25 $11,170 - $12,478
282 Added 4.01%
7,319 $300,000
Q4 2022

Feb 08, 2023

BUY
$40.06 - $43.59 $60,891 - $66,256
1,520 Added 27.55%
7,037 $288,000
Q3 2022

Oct 25, 2022

BUY
$39.59 - $44.52 $218,418 - $245,616
5,517 New
5,517 $222,000
Q2 2022

Aug 12, 2022

SELL
$38.15 - $46.44 $287,116 - $349,507
-7,526 Closed
0 $0
Q1 2022

May 11, 2022

SELL
$41.55 - $46.61 $97,559 - $109,440
-2,348 Reduced 23.78%
7,526 $341,000
Q4 2021

Feb 08, 2022

SELL
$43.72 - $52.45 $58,060 - $69,653
-1,328 Reduced 11.86%
9,874 $456,000
Q3 2021

Nov 02, 2021

BUY
$46.51 - $53.1 $17,394 - $19,859
374 Added 3.45%
11,202 $531,000
Q2 2021

Aug 11, 2021

SELL
$48.16 - $53.09 $9,487 - $10,458
-197 Reduced 1.79%
10,828 $561,000
Q1 2021

May 14, 2021

SELL
$49.44 - $56.01 $105,455 - $119,469
-2,133 Reduced 16.21%
11,025 $555,000
Q4 2020

Feb 12, 2021

SELL
$43.42 - $52.06 $221,398 - $265,453
-5,099 Reduced 27.93%
13,158 $685,000
Q3 2020

Nov 04, 2020

SELL
$42.46 - $45.34 $24,584 - $26,251
-579 Reduced 3.07%
18,257 $794,000
Q2 2020

Jul 28, 2020

BUY
$34.56 - $44.18 $650,972 - $832,174
18,836 New
18,836 $810,000
Q1 2020

Apr 21, 2020

SELL
$31.56 - $47.91 $1.21 Million - $1.84 Million
-38,470 Closed
0 $0
Q4 2019

Feb 12, 2020

SELL
$34.65 - $46.53 $25,121 - $33,734
-725 Reduced 1.85%
38,470 $1.76 Million
Q3 2019

Nov 07, 2019

BUY
$35.59 - $37.64 $1.15 Million - $1.22 Million
32,449 Added 481.01%
39,195 $1.4 Million
Q2 2019

Aug 06, 2019

SELL
N/A
-41,020 Reduced 85.88%
6,746 $269,000
Q1 2019

May 06, 2019

SELL
N/A
-16,788 Reduced 26.01%
47,766 $1.99 Million
Q4 2018

Feb 11, 2019

SELL
N/A
-5,181 Reduced 7.43%
64,554 $2.36 Million
Q3 2018

Nov 14, 2018

BUY
N/A
2,293 Added 3.4%
69,735 $3.39 Million
Q2 2018

Aug 14, 2018

SELL
N/A
-520 Reduced 0.77%
67,442 $2.9 Million
Q1 2018

May 14, 2018

SELL
N/A
-23,947 Reduced 26.06%
67,962 $2.85 Million
Q4 2017

Feb 14, 2018

BUY
N/A
49,976 Added 119.18%
91,909 $4 Million
Q3 2017

Nov 13, 2017

SELL
N/A
-25,693 Reduced 37.99%
41,933 $1.78 Million
Q2 2017

Aug 14, 2017

BUY
N/A
67,626
67,626 $2.91 Million

Others Institutions Holding XPH

About SPDR SER TR SPDR S&P PHARMACEU


  • Ticker XPH
  • Sector ETFs
  • Industry ETFs
More about XPH
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.